Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimers Disease-Reference-Cited by-同舟云学术

Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimers Disease

Published:2012 Issue:5 Volume:33 Page:341-353
ISSN:1421-9824
Container-title:Dementia and Geriatric Cognitive Disorders
language:en
Short-container-title:Dement Geriatr Cogn Disord

Author:

Cummings Jeffrey,Froelich Lutz,Black Sandra E.,Bakchine Serge,Bellelli Giuseppe,Molinuevo José L.,Kressig Reto W.,Downs Pamela,Caputo Angelika,Strohmaier Christine

Publisher

S. Karger AG

Subject

Psychiatry and Mental health,Cognitive Neuroscience,Geriatrics and Gerontology

Reference29 articles.

1. Predicting Caregiver Burden from Daily Functional Abilities of Patients with Mild Dementia

2. Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor Treatment

3. Predicting time to nursing home placement based on activities of daily living scores – a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil

4. Prediction of Institutionalisation in Dementia

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translation from Preclinical Research to Clinical Trials: Transdermal Drug Delivery for Neurodegenerative and Mental Disorders;Pharmaceutical Research;2024-06

2. Pharmacotherapy for patients with Alzheimer’s disease;Journal of the Korean Medical Association;2024-03-10

3. The influence of heat stress on the antioxidant protection glutathione link and the content of lipid peroxidation products in chicken liver;The Animal Biology;2023-12

4. Turning the Spotlight to Cholinergic Pharmacotherapy of the Human Language System;CNS Drugs;2023-06-21

5. Tratamiento del deterioro cognitivo;Medicine - Programa de Formación Médica Continuada Acreditado;2023-03